期刊
JOURNAL OF MOLECULAR MEDICINE-JMM
卷 92, 期 7, 页码 697-707出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00109-014-1165-y
关键词
Non-small-cell lung cancer; Oncogenic drivers; TKIs; RTKs; Acquired resistance
资金
- Lombardi Comprehensive Cancer Center at Georgetown University
In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following molecular profiling has dramatically changed the way advanced adenocarcinoma is treated. However, tumor cells inevitably acquire resistance to such therapies, circumventing any sustained clinical benefit. As the genomic classification of lung cancer continues to evolve and as the mechanisms of acquired resistance to targeted therapies become elucidated and more improved target-specific drugs come into sight, the future will see more promising results from the clinic through the development of new therapeutic strategies to overcome, or prevent the development of, resistance for lung cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据